JW Pharmaceutical announced on January 15 that its chromogenic assay designed to assess the severity of 'hemophilia' in patients using 'Hemlibra' has been commercialized in South Korea.

The Ministry of Health and Welfare (MOHW) has newly established a non-reimbursable CSA testing criterion, effective January 1.

CSA test is used to measure the activity of clotting factors in patients with hemophilia to diagnose the severity of the disease and to monitor the effectiveness of the treatment. It is particularly effective in accurately measuring factor VIII, which is deficient in patients with Hemophilia A. It is suitable for patients who use non-coagulant agents like Hemlibra.